Tofacitinib for Psoriatic Arthritis

Daniel Aletaha^{1

2}, Andreas Kerschbaumer¹, Josef S Smolen¹

Affiliations

Comment

Daniel Aletaha et al. N Engl J Med. 2018.

. 2018 Feb 22;378(8):775.

doi: 10.1056/NEJMc1715189.

Daniel Aletaha^{1

2}, Andreas Kerschbaumer¹, Josef S Smolen¹

No abstract available

Comment in

Tofacitinib for Psoriatic Arthritis.
Mease P, Gladman D. Mease P, et al. N Engl J Med. 2018 Feb 22;378(8):775-776. doi: 10.1056/NEJMc1715189. N Engl J Med. 2018. PMID: 29466165 No abstract available.

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS. Gladman D, et al. N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977. N Engl J Med. 2017. PMID: 29045207 Clinical Trial.
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS. Mease P, et al. N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975. N Engl J Med. 2017. PMID: 29045212 Clinical Trial.